Filing Flows › Coherus Oncology (CHRS) › Q4 2024
Coherus Oncology (CHRS) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 17, 2025
Coherus Oncology (CHRS) reported revenue of $54.1M for the fourth quarter 2024 (Q4 2024), -41% from a year earlier and -23% from the quarter before. Operating margin was -78.0%, net loss $50.7M (93.6% of revenue).
Coherus Oncology, Q4 2024: revenue $54.1M (-41% year over year), operating margin -78.0%, net loss $50.7M, operating cash flow $28.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $54.1M | -23% | -41% |
| Operating profit | −$42.2M | — | — |
| Net earnings | −$50.7M | — | — |
| Operating cash flow | $28.6M | — | — |
What changed
Revenue was $54.1M in Q4 2024, down 41% year over year and down 23% from the previous quarter.
Operating costs exceeded revenue by $42.2M, an operating margin of -78.0%. Total costs fell 40% while revenue fell 41%. The quarter ended with a net loss of $50.7M, wider than the previous quarter's $10.8M loss.
Operating cash flow was $28.6M. Non-cash charges added back $300K of depreciation and amortization and $6.4M of share-based compensation. Working capital and other items added $72.6M.
Questions
What was Coherus Oncology's revenue in the fourth quarter 2024?
Coherus Oncology (CHRS) reported revenue of $54.1M for the fourth quarter 2024 (Q4 2024), -41% from a year earlier and -23% from the quarter before.
Was Coherus Oncology profitable in the fourth quarter 2024?
Operating loss was $42.2M (-78.0% of revenue) and net loss $50.7M.
Source: Coherus Oncology 10-K on SEC EDGAR.